Most women spend years worrying about breast cancer and very little time worrying about their heart. The statistics tell the opposite story. Heart disease kills more women than all cancers combined, and its timing, peaking after menopause, is not a coincidence of age alone.
Estrogen has been doing cardiovascular work your entire adult life. When it leaves, you feel the consequences in your joints, your sleep, your mood. What's harder to feel, and therefore easier to ignore: is what's changing in your arteries.
What estrogen was doing for your heart
Estrogen acts on cardiovascular tissue in multiple, overlapping ways. It raises HDL ("good") cholesterol, lowers LDL ("bad") cholesterol, and reduces triglycerides — a favorable lipid profile that persists throughout reproductive life and reverses noticeably after menopause. Estrogen also keeps blood vessels flexible by promoting nitric oxide production, which causes arterial walls to dilate rather than stiffen. Arterial stiffness is a direct driver of blood pressure and heart attack risk.
There's more: estrogen has anti-inflammatory effects on the endothelium (the lining of blood vessels) that reduce the atherosclerotic plaque buildup responsible for most heart attacks. It also improves insulin sensitivity, which explains why metabolic syndrome — a cluster of risk factors including abdominal fat, elevated blood sugar, and high triglycerides: becomes substantially more common after menopause.
The original Women's Health Initiative (WHI) 2002 findings caused many women and doctors to abandon HRT due to cardiovascular concerns. The subsequent reanalysis told a more nuanced story: the cardiovascular risk was concentrated in women who started HRT more than 10 years after menopause onset: women in whom atherosclerosis had already progressed. Women who started within the 10-year window showed cardiovascular benefit. This is the "timing hypothesis" or "window of opportunity," now the basis for updated guidance from NAMS, British Menopause Society, and the FDA's February 2026 label revision.
The lipid shift after menopause
In the 12 months following menopause, LDL cholesterol rises an average of 10–14 points. Triglycerides rise. HDL drops. These are not small changes. This is roughly equivalent to a decade of normal aging compressed into one year. Women who never had cholesterol concerns often find themselves discussing statins for the first time in their early 50s, not realizing the menopause transition drove the shift.
This is one of the clearest arguments for a proactive cardiometabolic conversation at perimenopause, not at the point when risk has already accumulated. A lipid panel at 45 gives a baseline. Another at 52 shows the trajectory. That information shapes decisions about HRT, diet, exercise, and medication: before a cardiac event, not after.
Beyond a standard lipid panel: hsCRP (high-sensitivity C-reactive protein, a marker of arterial inflammation), fasting insulin and glucose, blood pressure trend over time, and coronary artery calcium (CAC) score if your cardiometabolic risk falls in the intermediate range. These give a fuller picture of cardiometabolic health than cholesterol alone, and are worth discussing with your primary care doctor or cardiologist at or after menopause.
The HRT and heart question, answered clearly
In women without contraindications, who are under 60 and within 10 years of menopause onset, the cardiovascular benefit-risk balance for HRT is favorable. This is the consensus position of every major menopause organization in 2026. The nuance: women over 60, or more than 10 years post-menopause, should have an individualized conversation with their doctor, as the balance shifts in that population.
Contraindications remain. Women with a personal history of blood clots, certain types of cardiovascular disease, or hormone-sensitive cancers require a different risk-benefit discussion. Transdermal estrogen (patch, gel) has a lower clot risk than oral estrogen: this distinction matters for women with certain risk factors.
What to discuss with your doctor
Request a full cardiometabolic panel at perimenopause (mid-40s): lipids, fasting glucose, insulin, blood pressure, hsCRP, and body composition. This is your baseline.
Ask specifically about cardiovascular risk in the context of menopause: not just "is my cholesterol OK" but "what does my overall risk trajectory look like over the next 10 years."
If you're considering HRT, ask your doctor to address the timing hypothesis specifically and where you fall in the window of opportunity.
Know the atypical heart attack symptoms in women: fatigue, nausea, jaw or arm pain, back pain, shortness of breath, and feeling of dread or impending doom: without classic chest pain. These are missed because they don't match the male presentation pattern.
Women are significantly underrepresented in cardiovascular clinical trials and are undertreated for heart disease even after diagnosis. If you feel your cardiovascular concerns aren't being taken seriously, asking for a referral to a cardiologist: specifically one familiar with women's cardiovascular health: is entirely appropriate. Several major medical centers now have dedicated women's heart health programs that apply sex-specific cardiovascular risk models.
References
- Rossouw JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297(13):1465–1477.
- Manson JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality. JAMA. 2017;318(10):927–938.
- Boardman HMP, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev. 2015;(3):CD002229.
- FDA. Labeling changes approved for menopausal hormone therapy products. February 2026.
- Mosca L, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women. Circulation. 2011;123(11):1243–1262.